# Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

> **NCT00348998** · PHASE2 · UNKNOWN · sponsor: **Virginia Mason Hospital/Medical Center** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** bicalutamide
- **DRUG:** goserelin acetate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00348998
- **Lead sponsor:** Virginia Mason Hospital/Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348998, "Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00348998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*